866-997-4948(US-Canada Toll Free)

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 68 Pages

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) - Overview
Inclusion Body Myositis (IBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
KPI Therapeutics Inc
Milo Biotechnology LLC
Nobelpharma Co Ltd
Orphazyme ApS
Ultragenyx Pharmaceutical Inc
Inclusion Body Myositis (IBM) - Drug Profiles
AAV1-Follistatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aceneuramic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALZ-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arimoclomol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GNE for Hereditary Inclusion Body Myopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-001P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Discontinued Products
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Inclusion Body Myositis (IBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma Inc, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by KPI Therapeutics Inc, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Orphazyme ApS, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
Inclusion Body Myositis (IBM) - Dormant Projects, H1 2017
Inclusion Body Myositis (IBM) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Inclusion Body Myositis (IBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *